270 related articles for article (PubMed ID: 22285893)
1. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer.
Chan CJ; Andrews DM; Smyth MJ
Curr Opin Immunol; 2012 Apr; 24(2):246-51. PubMed ID: 22285893
[TBL] [Abstract][Full Text] [Related]
2. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance.
Fuchs A; Colonna M
Semin Cancer Biol; 2006 Oct; 16(5):359-66. PubMed ID: 16904340
[TBL] [Abstract][Full Text] [Related]
3. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
[TBL] [Abstract][Full Text] [Related]
4. [Nectins and nectin-like receptors DNAM-1 and CRTAM: new ways for tumor escape].
Catros V; Dessarthe B; Thedrez A; Toutirais O
Med Sci (Paris); 2014 May; 30(5):537-43. PubMed ID: 24939541
[TBL] [Abstract][Full Text] [Related]
5. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
[TBL] [Abstract][Full Text] [Related]
6. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
[TBL] [Abstract][Full Text] [Related]
7. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.
de Andrade LF; Smyth MJ; Martinet L
Immunol Cell Biol; 2014 Mar; 92(3):237-44. PubMed ID: 24343663
[TBL] [Abstract][Full Text] [Related]
8. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM.
Boles KS; Barchet W; Diacovo T; Cella M; Colonna M
Blood; 2005 Aug; 106(3):779-86. PubMed ID: 15811952
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226.
Liu J; Qian X; Chen Z; Xu X; Gao F; Zhang S; Zhang R; Qi J; Gao GF; Yan J
J Immunol; 2012 Jun; 188(11):5511-20. PubMed ID: 22547693
[TBL] [Abstract][Full Text] [Related]
10. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.
Jin HS; Park Y
BMB Rep; 2021 Jan; 54(1):2-11. PubMed ID: 33298247
[TBL] [Abstract][Full Text] [Related]
11. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
[TBL] [Abstract][Full Text] [Related]
12. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
13. Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells.
Arase N; Takeuchi A; Unno M; Hirano S; Yokosuka T; Arase H; Saito T
Int Immunol; 2005 Sep; 17(9):1227-37. PubMed ID: 16091383
[TBL] [Abstract][Full Text] [Related]
14. Competition of cell adhesion and immune recognition: insights into the interaction between CRTAM and nectin-like 2.
Zhang S; Lu G; Qi J; Li Y; Zhang Z; Zhang B; Fan Z; Yan J; Gao GF
Structure; 2013 Aug; 21(8):1430-9. PubMed ID: 23871486
[TBL] [Abstract][Full Text] [Related]
15. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
16. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
17. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
[TBL] [Abstract][Full Text] [Related]
18. Emergence of the CD226 Axis in Cancer Immunotherapy.
Conner M; Hance KW; Yadavilli S; Smothers J; Waight JD
Front Immunol; 2022; 13():914406. PubMed ID: 35812451
[TBL] [Abstract][Full Text] [Related]
19. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
20. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.
Wesa AK; Storkus WJ
Cell Death Differ; 2008 Jan; 15(1):51-7. PubMed ID: 17948028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
